About this trial
Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D. Fishberg, MD, and Jeffrey N. Feldman, MD. The overarching goal of the lipid workgroup is to enhance the treatment of lipid disorders in those patients with abnormal lipid levels by improving access to resources at the primary care practice level and specialty level. We aim to develop a model for primary and secondary prevention that integrates guidelines for treatment at the practice level. Our primary objective is to identify high-risk patients by utilizing the electronic health record and partnering with patients' primary care providers to provide comprehensive medical management.
Eligibility criteria
Qualifiers
LDL-C ≥160 mg/dL
Untreated LDL-C ≥190 with family history of CAD
Prior MI and currently without optimized lipid-lowering therapy
Family history of CAD in first degree relative
Disqualifiers
Individuals who are pregnant
Individuals who are incarcerated
Individuals with a terminal illness
Individuals who do not consent
Trial design
Treatments tested in this trial
- Supportive care
Treatment groups
Sponsors and collaborators
Atlantic Health System
Lead sponsor
Regeneron Pharmaceuticals
Collaborator